SARS CoV subunit vaccine: antibody-mediated neutralisation and enhancement.
Identifieur interne : 001296 ( PubMed/Checkpoint ); précédent : 001295; suivant : 001297SARS CoV subunit vaccine: antibody-mediated neutralisation and enhancement.
Auteurs : M. Jaume [République populaire de Chine] ; M S Yip ; Y W Kam ; C Y Cheung ; F. Kien ; A. Roberts ; P H Li ; I. Dutry ; N. Escriou ; M. Daeron ; R. Bruzzone ; K. Subbarao ; J S M. Peiris ; B. Nal ; R. AltmeyerSource :
- Hong Kong medical journal = Xianggang yi xue za zhi [ 1024-2708 ] ; 2012.
Descripteurs français
- KwdFr :
- Animaux, Anticorps antiviraux (métabolisme), Anticorps neutralisants (métabolisme), Concentration en ions d'hydrogène, Cysteine proteases (métabolisme), Facilitation dépendante des anticorps, Glycoprotéine de spicule des coronavirus, Glycoprotéines membranaires (immunologie), Humains, Lignée cellulaire tumorale, Monocytes, Peptidyl-Dipeptidase A (métabolisme), Protéines de l'enveloppe virale (immunologie), Pénétration virale, Récepteur Fc (métabolisme), Souris, Souris de lignée BALB C, Syndrome respiratoire aigu sévère (immunologie), Vaccins, Virus du SRAS (immunologie), Virus du SRAS (physiologie).
- MESH :
- immunologie : Glycoprotéines membranaires, Protéines de l'enveloppe virale, Syndrome respiratoire aigu sévère, Virus du SRAS.
- métabolisme : Anticorps antiviraux, Anticorps neutralisants, Cysteine proteases, Peptidyl-Dipeptidase A, Récepteur Fc.
- physiologie : Virus du SRAS.
- Animaux, Concentration en ions d'hydrogène, Facilitation dépendante des anticorps, Glycoprotéine de spicule des coronavirus, Humains, Lignée cellulaire tumorale, Monocytes, Pénétration virale, Souris, Souris de lignée BALB C, Vaccins.
English descriptors
- KwdEn :
- Animals, Antibodies, Neutralizing (metabolism), Antibodies, Viral (metabolism), Antibody-Dependent Enhancement, Cell Line, Tumor, Cysteine Proteases (metabolism), Humans, Hydrogen-Ion Concentration, Membrane Glycoproteins (immunology), Mice, Mice, Inbred BALB C, Monocytes, Peptidyl-Dipeptidase A (metabolism), Receptors, Fc (metabolism), SARS Virus (immunology), SARS Virus (physiology), Severe Acute Respiratory Syndrome (immunology), Spike Glycoprotein, Coronavirus, Vaccines, Viral Envelope Proteins (immunology), Virus Internalization.
- MESH :
- chemical , immunology : Membrane Glycoproteins, Viral Envelope Proteins.
- chemical , metabolism : Antibodies, Neutralizing, Antibodies, Viral, Cysteine Proteases, Peptidyl-Dipeptidase A, Receptors, Fc.
- immunology : SARS Virus, Severe Acute Respiratory Syndrome.
- physiology : SARS Virus.
- Animals, Antibody-Dependent Enhancement, Cell Line, Tumor, Humans, Hydrogen-Ion Concentration, Mice, Mice, Inbred BALB C, Monocytes, Spike Glycoprotein, Coronavirus, Vaccines, Virus Internalization.
Abstract
1. A SARS vaccine was produced based on recombinant native full-length Spike-protein trimers (triSpike) and efficient establishment of a vaccination procedure in rodents. 2. Antibody-mediated enhancement of SARS-CoV infection with anti-SARS-CoV Spike immune-serum was observed in vitro. 3. Antibody-mediated infection of SARS-CoV triggers entry into human haematopoietic cells via an FcγR-dependent and ACE2-, pH-, cysteine-protease-independent pathways. 4. The antibody-mediated enhancement phenomenon is not a mandatory component of the humoral immune response elicited by SARS vaccines, as pure neutralising antibody only could be obtained. 5. Occurrence of immune-mediated enhancement of SARS-CoV infection raises safety concerns regarding the use of SARS-CoV vaccine in humans and enables new ways to investigate SARS pathogenesis (tropism and immune response deregulation).
PubMed: 22311359
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:22311359Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">SARS CoV subunit vaccine: antibody-mediated neutralisation and enhancement.</title><author><name sortKey="Jaume, M" sort="Jaume, M" uniqKey="Jaume M" first="M" last="Jaume">M. Jaume</name><affiliation wicri:level="1"><nlm:affiliation>HKU-Pasteur Research Centre, 8 Sassoon Road, Hong Kong SAR, China. breizh@hku.hk</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>HKU-Pasteur Research Centre, 8 Sassoon Road, Hong Kong SAR</wicri:regionArea><wicri:noRegion>Hong Kong SAR</wicri:noRegion></affiliation></author><author><name sortKey="Yip, M S" sort="Yip, M S" uniqKey="Yip M" first="M S" last="Yip">M S Yip</name></author><author><name sortKey="Kam, Y W" sort="Kam, Y W" uniqKey="Kam Y" first="Y W" last="Kam">Y W Kam</name></author><author><name sortKey="Cheung, C Y" sort="Cheung, C Y" uniqKey="Cheung C" first="C Y" last="Cheung">C Y Cheung</name></author><author><name sortKey="Kien, F" sort="Kien, F" uniqKey="Kien F" first="F" last="Kien">F. Kien</name></author><author><name sortKey="Roberts, A" sort="Roberts, A" uniqKey="Roberts A" first="A" last="Roberts">A. Roberts</name></author><author><name sortKey="Li, P H" sort="Li, P H" uniqKey="Li P" first="P H" last="Li">P H Li</name></author><author><name sortKey="Dutry, I" sort="Dutry, I" uniqKey="Dutry I" first="I" last="Dutry">I. Dutry</name></author><author><name sortKey="Escriou, N" sort="Escriou, N" uniqKey="Escriou N" first="N" last="Escriou">N. Escriou</name></author><author><name sortKey="Daeron, M" sort="Daeron, M" uniqKey="Daeron M" first="M" last="Daeron">M. Daeron</name></author><author><name sortKey="Bruzzone, R" sort="Bruzzone, R" uniqKey="Bruzzone R" first="R" last="Bruzzone">R. Bruzzone</name></author><author><name sortKey="Subbarao, K" sort="Subbarao, K" uniqKey="Subbarao K" first="K" last="Subbarao">K. Subbarao</name></author><author><name sortKey="Peiris, J S M" sort="Peiris, J S M" uniqKey="Peiris J" first="J S M" last="Peiris">J S M. Peiris</name></author><author><name sortKey="Nal, B" sort="Nal, B" uniqKey="Nal B" first="B" last="Nal">B. Nal</name></author><author><name sortKey="Altmeyer, R" sort="Altmeyer, R" uniqKey="Altmeyer R" first="R" last="Altmeyer">R. Altmeyer</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2012">2012</date><idno type="RBID">pubmed:22311359</idno><idno type="pmid">22311359</idno><idno type="wicri:Area/PubMed/Corpus">001401</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001401</idno><idno type="wicri:Area/PubMed/Curation">001401</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001401</idno><idno type="wicri:Area/PubMed/Checkpoint">001296</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001296</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">SARS CoV subunit vaccine: antibody-mediated neutralisation and enhancement.</title><author><name sortKey="Jaume, M" sort="Jaume, M" uniqKey="Jaume M" first="M" last="Jaume">M. Jaume</name><affiliation wicri:level="1"><nlm:affiliation>HKU-Pasteur Research Centre, 8 Sassoon Road, Hong Kong SAR, China. breizh@hku.hk</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>HKU-Pasteur Research Centre, 8 Sassoon Road, Hong Kong SAR</wicri:regionArea><wicri:noRegion>Hong Kong SAR</wicri:noRegion></affiliation></author><author><name sortKey="Yip, M S" sort="Yip, M S" uniqKey="Yip M" first="M S" last="Yip">M S Yip</name></author><author><name sortKey="Kam, Y W" sort="Kam, Y W" uniqKey="Kam Y" first="Y W" last="Kam">Y W Kam</name></author><author><name sortKey="Cheung, C Y" sort="Cheung, C Y" uniqKey="Cheung C" first="C Y" last="Cheung">C Y Cheung</name></author><author><name sortKey="Kien, F" sort="Kien, F" uniqKey="Kien F" first="F" last="Kien">F. Kien</name></author><author><name sortKey="Roberts, A" sort="Roberts, A" uniqKey="Roberts A" first="A" last="Roberts">A. Roberts</name></author><author><name sortKey="Li, P H" sort="Li, P H" uniqKey="Li P" first="P H" last="Li">P H Li</name></author><author><name sortKey="Dutry, I" sort="Dutry, I" uniqKey="Dutry I" first="I" last="Dutry">I. Dutry</name></author><author><name sortKey="Escriou, N" sort="Escriou, N" uniqKey="Escriou N" first="N" last="Escriou">N. Escriou</name></author><author><name sortKey="Daeron, M" sort="Daeron, M" uniqKey="Daeron M" first="M" last="Daeron">M. Daeron</name></author><author><name sortKey="Bruzzone, R" sort="Bruzzone, R" uniqKey="Bruzzone R" first="R" last="Bruzzone">R. Bruzzone</name></author><author><name sortKey="Subbarao, K" sort="Subbarao, K" uniqKey="Subbarao K" first="K" last="Subbarao">K. Subbarao</name></author><author><name sortKey="Peiris, J S M" sort="Peiris, J S M" uniqKey="Peiris J" first="J S M" last="Peiris">J S M. Peiris</name></author><author><name sortKey="Nal, B" sort="Nal, B" uniqKey="Nal B" first="B" last="Nal">B. Nal</name></author><author><name sortKey="Altmeyer, R" sort="Altmeyer, R" uniqKey="Altmeyer R" first="R" last="Altmeyer">R. Altmeyer</name></author></analytic><series><title level="j">Hong Kong medical journal = Xianggang yi xue za zhi</title><idno type="ISSN">1024-2708</idno><imprint><date when="2012" type="published">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Neutralizing (metabolism)</term><term>Antibodies, Viral (metabolism)</term><term>Antibody-Dependent Enhancement</term><term>Cell Line, Tumor</term><term>Cysteine Proteases (metabolism)</term><term>Humans</term><term>Hydrogen-Ion Concentration</term><term>Membrane Glycoproteins (immunology)</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Monocytes</term><term>Peptidyl-Dipeptidase A (metabolism)</term><term>Receptors, Fc (metabolism)</term><term>SARS Virus (immunology)</term><term>SARS Virus (physiology)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Spike Glycoprotein, Coronavirus</term><term>Vaccines</term><term>Viral Envelope Proteins (immunology)</term><term>Virus Internalization</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Anticorps antiviraux (métabolisme)</term><term>Anticorps neutralisants (métabolisme)</term><term>Concentration en ions d'hydrogène</term><term>Cysteine proteases (métabolisme)</term><term>Facilitation dépendante des anticorps</term><term>Glycoprotéine de spicule des coronavirus</term><term>Glycoprotéines membranaires (immunologie)</term><term>Humains</term><term>Lignée cellulaire tumorale</term><term>Monocytes</term><term>Peptidyl-Dipeptidase A (métabolisme)</term><term>Protéines de l'enveloppe virale (immunologie)</term><term>Pénétration virale</term><term>Récepteur Fc (métabolisme)</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Syndrome respiratoire aigu sévère (immunologie)</term><term>Vaccins</term><term>Virus du SRAS (immunologie)</term><term>Virus du SRAS (physiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Membrane Glycoproteins</term><term>Viral Envelope Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Antibodies, Neutralizing</term><term>Antibodies, Viral</term><term>Cysteine Proteases</term><term>Peptidyl-Dipeptidase A</term><term>Receptors, Fc</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Glycoprotéines membranaires</term><term>Protéines de l'enveloppe virale</term><term>Syndrome respiratoire aigu sévère</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Anticorps antiviraux</term><term>Anticorps neutralisants</term><term>Cysteine proteases</term><term>Peptidyl-Dipeptidase A</term><term>Récepteur Fc</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Antibody-Dependent Enhancement</term><term>Cell Line, Tumor</term><term>Humans</term><term>Hydrogen-Ion Concentration</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Monocytes</term><term>Spike Glycoprotein, Coronavirus</term><term>Vaccines</term><term>Virus Internalization</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Concentration en ions d'hydrogène</term><term>Facilitation dépendante des anticorps</term><term>Glycoprotéine de spicule des coronavirus</term><term>Humains</term><term>Lignée cellulaire tumorale</term><term>Monocytes</term><term>Pénétration virale</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Vaccins</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">1. A SARS vaccine was produced based on recombinant native full-length Spike-protein trimers (triSpike) and efficient establishment of a vaccination procedure in rodents. 2. Antibody-mediated enhancement of SARS-CoV infection with anti-SARS-CoV Spike immune-serum was observed in vitro. 3. Antibody-mediated infection of SARS-CoV triggers entry into human haematopoietic cells via an FcγR-dependent and ACE2-, pH-, cysteine-protease-independent pathways. 4. The antibody-mediated enhancement phenomenon is not a mandatory component of the humoral immune response elicited by SARS vaccines, as pure neutralising antibody only could be obtained. 5. Occurrence of immune-mediated enhancement of SARS-CoV infection raises safety concerns regarding the use of SARS-CoV vaccine in humans and enables new ways to investigate SARS pathogenesis (tropism and immune response deregulation).</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22311359</PMID><DateCompleted><Year>2012</Year><Month>05</Month><Day>30</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1024-2708</ISSN><JournalIssue CitedMedium="Internet"><Volume>18 Suppl 2</Volume><PubDate><Year>2012</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Hong Kong medical journal = Xianggang yi xue za zhi</Title><ISOAbbreviation>Hong Kong Med J</ISOAbbreviation></Journal><ArticleTitle>SARS CoV subunit vaccine: antibody-mediated neutralisation and enhancement.</ArticleTitle><Pagination><MedlinePgn>31-6</MedlinePgn></Pagination><Abstract><AbstractText>1. A SARS vaccine was produced based on recombinant native full-length Spike-protein trimers (triSpike) and efficient establishment of a vaccination procedure in rodents. 2. Antibody-mediated enhancement of SARS-CoV infection with anti-SARS-CoV Spike immune-serum was observed in vitro. 3. Antibody-mediated infection of SARS-CoV triggers entry into human haematopoietic cells via an FcγR-dependent and ACE2-, pH-, cysteine-protease-independent pathways. 4. The antibody-mediated enhancement phenomenon is not a mandatory component of the humoral immune response elicited by SARS vaccines, as pure neutralising antibody only could be obtained. 5. Occurrence of immune-mediated enhancement of SARS-CoV infection raises safety concerns regarding the use of SARS-CoV vaccine in humans and enables new ways to investigate SARS pathogenesis (tropism and immune response deregulation).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jaume</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>HKU-Pasteur Research Centre, 8 Sassoon Road, Hong Kong SAR, China. breizh@hku.hk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yip</LastName><ForeName>M S</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Kam</LastName><ForeName>Y W</ForeName><Initials>YW</Initials></Author><Author ValidYN="Y"><LastName>Cheung</LastName><ForeName>C Y</ForeName><Initials>CY</Initials></Author><Author ValidYN="Y"><LastName>Kien</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Roberts</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>P H</ForeName><Initials>PH</Initials></Author><Author ValidYN="Y"><LastName>Dutry</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Escriou</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Daeron</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Bruzzone</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Subbarao</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Peiris</LastName><ForeName>J S M</ForeName><Initials>JS</Initials></Author><Author ValidYN="Y"><LastName>Nal</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Altmeyer</LastName><ForeName>R</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AI95357</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Hong Kong Med J</MedlineTA><NlmUniqueID>9512509</NlmUniqueID><ISSNLinking>1024-2708</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011961">Receptors, Fc</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014612">Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D057056">Cysteine Proteases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.15.1</RegistryNumber><NameOfSubstance UI="D007703">Peptidyl-Dipeptidase A</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.17.-</RegistryNumber><NameOfSubstance UI="C413524">angiotensin converting enzyme 2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019067" MajorTopicYN="Y">Antibody-Dependent Enhancement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057056" MajorTopicYN="N">Cysteine Proteases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006863" MajorTopicYN="N">Hydrogen-Ion Concentration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009000" MajorTopicYN="N">Monocytes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007703" MajorTopicYN="N">Peptidyl-Dipeptidase A</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011961" MajorTopicYN="N">Receptors, Fc</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014612" MajorTopicYN="N">Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053586" MajorTopicYN="Y">Virus Internalization</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22311359</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>République populaire de Chine</li></country></list><tree><noCountry><name sortKey="Altmeyer, R" sort="Altmeyer, R" uniqKey="Altmeyer R" first="R" last="Altmeyer">R. Altmeyer</name><name sortKey="Bruzzone, R" sort="Bruzzone, R" uniqKey="Bruzzone R" first="R" last="Bruzzone">R. Bruzzone</name><name sortKey="Cheung, C Y" sort="Cheung, C Y" uniqKey="Cheung C" first="C Y" last="Cheung">C Y Cheung</name><name sortKey="Daeron, M" sort="Daeron, M" uniqKey="Daeron M" first="M" last="Daeron">M. Daeron</name><name sortKey="Dutry, I" sort="Dutry, I" uniqKey="Dutry I" first="I" last="Dutry">I. Dutry</name><name sortKey="Escriou, N" sort="Escriou, N" uniqKey="Escriou N" first="N" last="Escriou">N. Escriou</name><name sortKey="Kam, Y W" sort="Kam, Y W" uniqKey="Kam Y" first="Y W" last="Kam">Y W Kam</name><name sortKey="Kien, F" sort="Kien, F" uniqKey="Kien F" first="F" last="Kien">F. Kien</name><name sortKey="Li, P H" sort="Li, P H" uniqKey="Li P" first="P H" last="Li">P H Li</name><name sortKey="Nal, B" sort="Nal, B" uniqKey="Nal B" first="B" last="Nal">B. Nal</name><name sortKey="Peiris, J S M" sort="Peiris, J S M" uniqKey="Peiris J" first="J S M" last="Peiris">J S M. Peiris</name><name sortKey="Roberts, A" sort="Roberts, A" uniqKey="Roberts A" first="A" last="Roberts">A. Roberts</name><name sortKey="Subbarao, K" sort="Subbarao, K" uniqKey="Subbarao K" first="K" last="Subbarao">K. Subbarao</name><name sortKey="Yip, M S" sort="Yip, M S" uniqKey="Yip M" first="M S" last="Yip">M S Yip</name></noCountry><country name="République populaire de Chine"><noRegion><name sortKey="Jaume, M" sort="Jaume, M" uniqKey="Jaume M" first="M" last="Jaume">M. Jaume</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001296 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001296 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:22311359
|texte= SARS CoV subunit vaccine: antibody-mediated neutralisation and enhancement.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:22311359" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |